Description:
Xenobiotics in Chemical Carcinogenesis: Translational Aspects in Toxicology covers the translational toxicology of xenobiotics substances in carcinogenesis by explaining the toxicokinetic and toxicodynamic, toxicogenomic, biotransformation, and resistance mechanisms in the human body. The book begins with a historical review and link to future prospects for chemical carcinogenesis. It discusses major environmental xenobiotics and their risks in inducing cancer, along with content on toxic xenobiotics and their routes of exposure in humans, the role of xenobiotic metabolism in carcinogenesis, and the toxicokinetic and toxicodynamic of xenobiotics in cancer development.
Lastly, the book explores current achievements such as using toxicogenomics for predicting the carcinogenicity of xenobiotic substances and the challenges posed by carcinogenic xenobiotic substances when examining preventive methods, diagnosis, and the development of anticancer drugs for specific toxicants.
Brief description: Dr. Dhruv Kumar is a Senior Associate Professor at School of Health Sciences and Technology, UPES University, Dehradun, India and his current research is focused on autophagy, cancer cell metabolism, tumour microenvironment, exosomes, mutational heterogeneity, cancer prevention, drug designing, NGS and COVID-19. After completion of B.Sc. in Chemistry from Banaras Hindu University (BHU) and M.Sc. in Bioinformatics from University of Allahabad, India, he has completed his Ph.D. in Cellular, Molecular and Industrial Biology from the University of Bologna (UNIBO), under highly prestigious fellowship, Indo-Italian Government fellowship. After his Ph.D., he obtained Postdoctoral training at the University of Kansas Medical Center, USA. During his Postdoctoral training, he worked towards understanding the molecular mechanism(s) of autophagy regulation and apoptosis in cancer stem cells (prostate, pancreatic and breast), focusing on the metabolic cross-talk between the tumour microenvironment (cancer associated fibroblast (CAF)) and head and neck squamous cell carcinoma (HNSCC) via HGF/c-MET and bFGF/FGFR signalling pathways. He has also worked on structure based drug designing for several cancers, COVID-19, mutational heterogeneity in cancer. Currently, his lab is focusing on metabolic heterogeneity in solid tumours and structure based drug designing for cancer and COVID-19. He has published more than 100 research articles, reviews and book chapters in reputed journals.